Management of the Various Causes of Thyrotoxicosis

  • Douglas S. Ross
Part of the Contemporary Endocrinology book series (COE, volume 2)


A number of different clinical entities can cause thyrotoxicosis. It is essential that the correct etiology be identified, since appropriate therapy depends on the mechanism of the thyrotoxicosis. Table 1 lists the various causes of thyrotoxicosis. Thyrotoxicosis commonly results from de novo synthesis of thyroid hormone within the thyroid. Patients with these disorders will have an elevated 24-h radioiodine uptake and can be treated with therapy directed against the thyroid gland such as thionamides, radio-iodine, or surgery. In contrast, thyrotoxicosis with a low 24-h radioiodine uptake indicates either inflammation and destruction of thyroid tissue with release of preformed hormone into the circulation, or an extrathyroidal source of thyroid hormone. Thyrotoxicosis resulting from thyroid inflammation is not associated with new hormone synthesis, and thionamide therapy is not appropriate for these disorders.


Thyroid Hormone Antithyroid Drug Radioiodine Therapy Radioiodine Uptake Subacute Thyroiditis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha-and ß-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev 1983; 4: 378–388.PubMedCrossRefGoogle Scholar
  2. 2.
    Geffner DL, Hershman JM. 13-adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93: 61–68.PubMedCrossRefGoogle Scholar
  3. 3.
    Wiersinga WM, Toubler JL. The influence of 0-adrenergic blocking agents on plasma thyroxine and triiodothyronine. J Clin Endocrinol Metab 1977; 45: 293–298.PubMedCrossRefGoogle Scholar
  4. 4.
    Perrild H, Hansen JM, Skovsted L, Christensen LK. Different effects of propranolol, alprenolol, sotalol, atenolol and metoprolol on serum T3 and rT3 in hyperthyroidism. Clin Endocrinol 1983; 18: 139–142.CrossRefGoogle Scholar
  5. 5.
    Gerst PH, Fildes J, Baylor P, Zonszein J. Long-acting 0-adrenergic antagonists as preparation for surgery in thyrotoxicosis. Arch Surg 1986; 121: 838–840.PubMedCrossRefGoogle Scholar
  6. 6.
    Sherif IH, Oyan WT, Bosairi S, Carrascal SM. Treatment of hyperthyroidism in pregnancy. Acta Obstet Gynecol Scand 1991; 70: 461–463.PubMedCrossRefGoogle Scholar
  7. 7.
    Davies TF. New thinking on the immunology of Graves’ disease. Thyroid Today 1992; 15 (4): 1–11.Google Scholar
  8. 8.
    Fatourechi V, McConahey WM, Woolner LB. Hyperthyroidijsm associated with histologic Hashimoto’s thyroiditis. Mayo Clin Proc 1971; 41: 682–689.Google Scholar
  9. 9.
    Martin FIR, Tress BW, Colman PG, Dream DR. Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med 1993; 95: 78–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Cooper DS. Antithyroid drugs. N Engl J Med 1984; 311: 1353–1362.PubMedCrossRefGoogle Scholar
  11. 11.
    Nareem N, Miner DJ, Amatruda JM. Methimazole: An alternative route of administration. J Clin Endocrinol Metab 1982; 54: 180, 181.Google Scholar
  12. 12.
    Walter RM, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves’ disease. Am J Med 1990; 88: 69, 70.Google Scholar
  13. 13.
    Gregoire G, Aris-Jilwan N, Ninet B, et al. Intravenous administration of propylthiouracil in treatment of a patient with Graves’ disease (abstract). 77th Annual Meeting, The Endocrine Society, 1995, abstract P3–464.Google Scholar
  14. 14.
    Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab 1987; 65: 719–723.PubMedCrossRefGoogle Scholar
  15. 15.
    Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab 1986; 63: 125–128.PubMedCrossRefGoogle Scholar
  16. 16.
    Mashio Y, Beniko M, Ikota A, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol 1988; 119: 139–144.PubMedGoogle Scholar
  17. 17.
    Gwinup G. Prospective randomized comparison of propylthiouracil. JAMA 1978; 239: 2457–2459.Google Scholar
  18. 18.
    Kampmann JP, Johansen K, Hansen JM, Helweg J. Propylthiouracil in human milk. Revision of a dogma. Lancet 1980; 1: 736–737.PubMedCrossRefGoogle Scholar
  19. 19.
    Werner MC, Romaldini JH, Bromberg N, et al. Adverse effects related to thionamide drugs and their dose regimen. Am J Med Sci 1989; 297: 216–219.PubMedCrossRefGoogle Scholar
  20. 20.
    Jackson IMD. Management of thyrotoxicosis. J Maine Med Assoc 1975; 66: 22–32.Google Scholar
  21. 21.
    Cooper DS, Goldminz D, Levin A, et al. Agranulocytosis associated with antithyroid drugs: Effects of patient age and drug dose. Ann Intern Med 1983; 98: 26–29.PubMedGoogle Scholar
  22. 22.
    Tamai H, Takaichi Y, Morita T, et al. Methimazole-induced agranulocytosis in Japanese patients with Graves’ disease. Clin Endocrinol 1989; 30: 525–530.CrossRefGoogle Scholar
  23. 23.
    Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med 1990; 150: 621–624.PubMedCrossRefGoogle Scholar
  24. 24.
    Weitzman SA, Stossel TP, Harmon DC, Daniels G, Maloof F, Ridgway EC. Antineutrophilic antibodies inGraves’ disease. Implications of thyrotropin binding to neutrophils. J Clin Invest 1985; 75: 119–123.PubMedCrossRefGoogle Scholar
  25. 25.
    Balkin MS, Buchholtz M, Ortiz J, Green AJ. Propylthiouracil (PTU)induced agranulocytosis treated with recombinant human granulocyte colonystimulating factor (G-CSF). Thyroid 1993; 3: 305–309.PubMedCrossRefGoogle Scholar
  26. 26.
    Liaw Y, Huang M, Fan K, et al. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. Ann Intern Med 1993; 118: 424–428.PubMedGoogle Scholar
  27. 27.
    Vasily DB, Tyler WB. Proplthiouracil-induced cutaneous vasculitis: Case presentations and review of the literature. JAMA 1980; 23: 458–461.Google Scholar
  28. 28.
    Takamatsu J, Hosoya T, Naito N, et al. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves’ disease. J Clin Endocrinol Metab 1988; 66: 147–152.PubMedCrossRefGoogle Scholar
  29. 29.
    Chen JJ, Ladenson PW. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves’ disease. J Clin Endocrinol Metab 1986; 63: 102–106.PubMedCrossRefGoogle Scholar
  30. 30.
    Ross DS, Daniels GH, Gouveia D. The use and limitations of a chemiluminescent thyrotropin assay as a single thyroid function test in an out-patient endocrine clinic. J Clin Endocrinol Metab 1990; 71: 764–769.PubMedCrossRefGoogle Scholar
  31. 31.
    Weetman AP. The immunomodulatory effects of antithyroid drugs. Thyroid 1994; 4: 145, 146.Google Scholar
  32. 32.
    Volpe R. Evidence that the immunosuppressive effects of antithryoid drugs are mediated through actions on the thyroid cell, modulating thymocyte-immunocyte signaling: A review. Thyroid 1994; 4: 217–223.CrossRefGoogle Scholar
  33. 33.
    Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid stimulating immunoglobulins in Graves’ disease: Evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab 1984; 58: 62–69.PubMedCrossRefGoogle Scholar
  34. 34.
    Solomon BL, Evaul JE, Burman KD, Wartofsky L. Remission rates with antithyroid drug therapy: Continued influence of iodine intake? Ann Intern Med 1987; 107: 510–512.PubMedGoogle Scholar
  35. 35.
    Codaccioni JL, Orgiazzi J, Blanc P, et al. Lasting remissions in patients treated for Graves’ hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab 1988; 67: 656–662.PubMedCrossRefGoogle Scholar
  36. 36.
    Kawai K, Tamai H, Matsubayashi S, et al. A study of untreated Graves’ patients with undetec-table TSH binding inhibior immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol 1995; 43: 551–556.CrossRefGoogle Scholar
  37. 37.
    Takaichi Y, Tamai H, Honda K, et al. The significance of thyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves’ disease treated with antithyroid drugs. J Clin Endocrinol Metab 1989; 68: 1097–1110.PubMedCrossRefGoogle Scholar
  38. 38.
    Greer MA, Kammer H, Bouma DJ. Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease. N Engl J Med 1977; 297: 173–176.PubMedCrossRefGoogle Scholar
  39. 39.
    Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol Metab 1987; 64: 1241–1245.PubMedCrossRefGoogle Scholar
  40. 40.
    Kralem Z, Baron E, Kahana L, et al. Changes in stimulating and blocking TSH receptor antibodies in a patient undergoing three cycles of transition from hypo-to hyperthyroidism and back to hypothyroidism. Clin Endocrinol 1992; 36: 211–216.CrossRefGoogle Scholar
  41. 41.
    Franklyn JA. Drug therapy: The management of hyperthyroidism. N Engl J Med 1994; 330: 1731–1738.PubMedCrossRefGoogle Scholar
  42. 42.
    Cho BY, Shong MH, Yi KH, Lee HK Koh C-S, Min HK. Evaluation of serum basal thyrotropin levels and tyrotropin receptor antibody activities as prognostic markers for discontinuation of antithyoid rug treatment in patients with Graves’ disease. Clin Endocrinol 1992; 36: 585–590.CrossRefGoogle Scholar
  43. 43.
    Yamamoto M, Igarashi T, Kimura S, Tsukamoto S, Togawa K, Ogata EN. Thyroid duppression test and outcome of hyperthyroidism treated with antithyoid drugs and triiodothyronine. J Clin Endocrinol Metab 1979; 48: 72–77.PubMedCrossRefGoogle Scholar
  44. 44.
    Talbot JN, Duron F, Aubert P, Milhaud G. Thyroglobulin, thyrotropin and thyrotropin binding inhibitory immunoglobulins assayed at the withdrawal of antithyroid drug therapy as predictors of relapse of Graves’ disease within one year. J Endocrinol Invest 1989; 12: 589–595.PubMedGoogle Scholar
  45. 45.
    McGregor M, Smith BR, Hall R, Peterson MM, Miller M, Dewar PJ. Prediction of relapse in hyperthyroid Graves’ disease. Lancet 1980;i:1101–1103.Google Scholar
  46. 46.
    Schleusener H, Schwander J, Holl G, et al. Do HLA-DR-typing and measurement of TSHreceptor antibodies help in the prediction of the clinical course of Graves’ thyrotoxicosis after antithyroid drug treatment? Acta Endocrinol 1987; 281 (Suppl): 318–324.Google Scholar
  47. 47.
    Romaldini JH, Bromberg N, Werner RS, et al. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 563–570.PubMedCrossRefGoogle Scholar
  48. 48.
    Reinwein D, Benker G, Lazarus JH, Alexander WD. European Multicenter Study Group on Antithyroid Drug Treatment. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab 1993; 76: 1516–1521.PubMedCrossRefGoogle Scholar
  49. 49.
    Hashizume K, Ichikawa K, Sakurai A, et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947–953.PubMedCrossRefGoogle Scholar
  50. 50.
    Hashizume K, Ichikawa K, Nishii Y, et al. Effect of administration of thyroxine on the risk of postpartum recurrence of hyperthyroid Graves’ disease. J Clin Endocrinol Metab 1992; 75: 6–10.PubMedCrossRefGoogle Scholar
  51. 51.
    McIver B, Rae PH, Beckett G, et al. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220–224.PubMedCrossRefGoogle Scholar
  52. 52.
    Tamai H, Hayaki I, Kawai K, et al. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves’ disease patients. J Clin Endocrinol Metab 1995; 80: 1481–1484.PubMedCrossRefGoogle Scholar
  53. 53.
    Doufas A, Mastorakos G, Mantzos J, Koutras DA. Recurrence of Graves’s disease is independent of thyroxine administration after medical therapy (abstract). Thyroid 1995;5:S–70.Google Scholar
  54. 54.
    Wiersinga WM. Immunosuppression of Graves’ hyperthyroidism-still an elusive goal. N Engl J Med 1996; 334: 265, 266.Google Scholar
  55. 55.
    Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129–135.PubMedCrossRefGoogle Scholar
  56. 56.
    Ross DS, Daniels GH, DeStefano P, et al. Use of adjunctive potassium iodide following radioactive iodine (1311) treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 1983; 57: 250–253.PubMedCrossRefGoogle Scholar
  57. 57.
    Sridama V, McCormick M, Kaplan EL, et al. Long-term follow-up study of compensated low-dose 131I therapy for Graves’ disease. N Engl J Med 1984; 311: 426–432.PubMedCrossRefGoogle Scholar
  58. 58.
    Rapoport B, Caplan R, DeGroot LJ. Low-dose sodium iodide I 131 therapy in Graves’ disease. JAMA 1973; 224: 1610–1613.Google Scholar
  59. 59.
    Goolden AW, Stewart JS. Long-term results from graded low dose radioactive iodine therapy for thyrotoxicosis. Clin Endocrinol 1986; 24: 217–222.CrossRefGoogle Scholar
  60. 60.
    Diamond T, Vine J, Smart R, Butler P. Thyrotoxic bone disease in women: A potentially reversible disorder. Ann Intern Med 1994; 120: 8–11.PubMedGoogle Scholar
  61. 61.
    Ross DS. Subclinical hyperthyroidism. in: Braverman LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid, 7th ed, Lippincott-Raven, Philadelphia, 1996, pp. 1016–1020.Google Scholar
  62. 62.
    Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992; 326: 1733–1738.PubMedCrossRefGoogle Scholar
  63. 63.
    Sridama V, DeGroot LJ. Treatment of Graves’ disease and the course of ophthalmopathy. Am J Med 1989; 87: 70–73.PubMedCrossRefGoogle Scholar
  64. 64.
    Gwinup G, Elias AN, Ascher MS. Effect on exophthalmos of various methods of treatment of Graves’ disease. JAMA 1982; 247: 2135–2138.Google Scholar
  65. 65.
    Bartalena L, Marcocci C, Bogazzi F, et al. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989; 321: 1349–1352.PubMedCrossRefGoogle Scholar
  66. 66.
    Ross DS, Ridgway EC, Daniels GH. Successful treatment of solitary toxic thyroid nodules with relatively low-dose iodine-131, with low prevalence of hypothyroidism. Ann Intern Med 1984; 101: 488–490.PubMedGoogle Scholar
  67. 67.
    Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med 1983; 309: 1473–1476.PubMedCrossRefGoogle Scholar
  68. 68.
    Mariotti S, Martino E, Francesconi M, et al. Serum thyroid autoantibodies as a risk factor for development of hypothyroidism after radioiodine therapy for a single ‘hot’ nodule. Acta Endocrinol (Copenhagen) 1986; 113: 500–507.Google Scholar
  69. 69.
    Nordyke RA, Gilbert FI Jr. Optimal iodine-131 dose for eliminating hyperthyroidism in Graves’ disease. J Nucl Med 1991; 32: 411–416.PubMedGoogle Scholar
  70. 70.
    Ferrar JJ, Toft AD. Iodine-131 treatment of hyperthyroidism: Current issues. Clin Endocrinol 1991; 35: 207–212.CrossRefGoogle Scholar
  71. 71.
    Peters H, Fisher L, Boyner U, et al. Radioiodine therapy of Graves’ hyperthyroidism: Standard vs calculated (131) iodine activity. Results from a prospective, randomized multicentre study. Eur J Clin Invest 1995; 25: 186–193.PubMedCrossRefGoogle Scholar
  72. 72.
    Jarlov AE, Heyedus L, Kristensen LO, et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol (Oxf) 1995; 43: 325–329.CrossRefGoogle Scholar
  73. 73.
    Shafer RB, Nuttall FQ. Acute changes in thyroid function in patients treated with radioiodine. Lancet 1975; 2: 635, 636.Google Scholar
  74. 74.
    Burch HB, Solomon BL, Wartofsky L, Burman KD. Discontinuing antithyroid therapy before ablation with radioiodine in Graves’ disease. Ann Intern Med 1994; 121: 553–559.PubMedGoogle Scholar
  75. 75.
    Velkeniers B, Cytryn R, Vanhaelst L, Jonkcheer MH. Treatment of hyperthyroidism with radio-iodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 1988; 2: 1127–1129.CrossRefGoogle Scholar
  76. 76.
    Clerc J, Izembart M, Dagousset F, et al. Influence of dose selection on absorbed dose profiles of radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. J Nucl Med 1993; 34: 387–393.PubMedGoogle Scholar
  77. 77.
    Tuttle RM, Patience T, Budd S. Treatment with propylthiouracil before radioiodine therapy is associated with a higher treatment failure rate than therapy with radioiodine alone in Graves’ disease. Thyroid 1995; 5: 243–247.PubMedCrossRefGoogle Scholar
  78. 78.
    Graham GD, Burman KD. Radioiodine treatment of Graves’ disease. An assessment of its potential risks. Ann Intern Med 1986; 105: 900–905.PubMedGoogle Scholar
  79. 79.
    Saenger EL, Thoma GE, Tompkins EA. Incidence of leukemia following treatment of hyperthyroidism; Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. JAMA 1968; 205: 147–154.Google Scholar
  80. 80.
    Dobyns DM, Shelene GE, Workman JB, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab 1974; 38: 976–998.PubMedCrossRefGoogle Scholar
  81. 81.
    Safa AM, Schumacher OP, Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975; 292: 167–171.PubMedCrossRefGoogle Scholar
  82. 82.
    Robertson JS, Gorman CA. Gonadal radiation dose and its genetic significance in radioiodine therapy of hyperthyroidism. J Nucl Med 1976; 17: 826–835.PubMedGoogle Scholar
  83. 83.
    Toft AD, Irvine WJ, Sinclair I, et al. Thyroid function after surgical treatment of thyrotoxicosis. A report of 100 cases treated with propranolol before operation. N Engl J Med 1978; 298: 643–647.PubMedCrossRefGoogle Scholar
  84. 84.
    Jortso E, Lennquist S, Lundstrom B, et al. The influence of remnant size, antithyroid antibodies, thyroid morphology, and lymphocytic infiltration on thyroid function after subtotal resection for hyperthyroidism. World J Surg 1987; 11: 365–371.PubMedCrossRefGoogle Scholar
  85. 85.
    Katlic MR, Grillo H, Wang C. Substernal goiter: Analysis of 80 patients from Massachusetts General Hospital. Am J Surg 1985; 149: 283–287.PubMedCrossRefGoogle Scholar
  86. 86.
    Marigold JH, Morgan AK, Earle OJ, et al. Lugol’s iodine: its effect on thyroid blood flow in patients with thyrotoxicosis. Br J Surg 1985; 72: 45–47.PubMedCrossRefGoogle Scholar
  87. 87.
    Feek CM, Sawers SA, Irvine WJ, et al. Combination of potassium iodide and propranolol in preparation of patients with Graves’ disease for thyroid surgery. N Engl J Med 1980; 302: 833–835.CrossRefGoogle Scholar
  88. 88.
    Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol 1991; 35: 439–442.CrossRefGoogle Scholar
  89. 89.
    Wu SY, Shyh TP, Chopra IJ, et al. Comparison of sodium ipodate (Oragrafin) and propylthiouracil in early treatment of hyperthyroidism. J Clin Endocrinol Metab 1982; 54: 630–634.PubMedCrossRefGoogle Scholar
  90. 90.
    Robuschi G, Manfredi A, Salvi M, et al. Effect of sodium ipodate and iodide on free T4 and free T3 concentrations in patients with Graves’ disease. J Endocrinol Invest 1986; 9: 287–291.PubMedGoogle Scholar
  91. 91.
    Shen DC, Wu SY, Chopra IJ, et al. Long-term treatment of Graves’ hyperthyroidism with sodium ipodate. J Clin Endocrinol Metab 1985; 61: 723–727.PubMedCrossRefGoogle Scholar
  92. 92.
    Martino E, Balzano S, Bartalena L, et al. Therapy of Graves’ disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest 1991; 14: 847–851.PubMedGoogle Scholar
  93. 93.
    Caldwell G, Errington M, Tift AD. Resistant hyperthyroidism induced by sodium ipodate used as treatment for Graves’ disease. Acta Endocrinol 1989; 120: 215, 216.Google Scholar
  94. 94.
    Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroidism Graves’ disease. Clin Endocrinol 1988; 28: 305–314.CrossRefGoogle Scholar
  95. 95.
    Chopra IJ, van Herle AJ, Korenman SG, et al. Use of sodium ipodate in management of hyperthyroidism in subacute thyroiditis. J Clin Endocrinol Metab 1995; 80: 2178–2180.PubMedCrossRefGoogle Scholar
  96. 96.
    Berkner PD, Starkman H, Person N. Acute L-thyroxine overdose: Therapy with sodium ipodate: Evaluation of clinical and physiologic parameters. J Emerg Med 1991; 9: 129–131.PubMedCrossRefGoogle Scholar
  97. 97.
    Wolff J, Chiakoff IL, Goldberg RC, Meier JR. The temporary nature of the inhibitor action of excess iodide on organic iodine synthesis in the normal thyroid. Endocrinology 1949; 45: 504–513.PubMedCrossRefGoogle Scholar
  98. 98.
    Kirkland RH. Impaired organic binding of radioiodine by the thyroid following radioiodine treatment of hyperthyroidism. J Clin Endocrinol Metab 1954; 14: 565–571.PubMedCrossRefGoogle Scholar
  99. 99.
    Philippou G, Koutras DA, Piperingos G, et al. The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. Clin Endocrinol 1992; 36: 573–578.CrossRefGoogle Scholar
  100. 100.
    Gamstedt A, Kagedal B, Tegler L. Serum free thyroid hormones are decreased by betamethasone treatment in Graves’ disease. Horm Metab Res 1988; 20: 54–56.PubMedCrossRefGoogle Scholar
  101. 101.
    Broussolle G, Ducottet X, Martin C, et al. Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal glands. J Endocrinol Invest 1989; 12: 37–42.PubMedGoogle Scholar
  102. 102.
    Martino E, Aghini-Lombardi F, Mariotti S, et al. Treatment of amiodarone-associated thyrotoxicosis by the simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986; 9: 201–207.PubMedGoogle Scholar
  103. 103.
    Turner JG, Brownlie BEW, Sadler WA, Jensen CH. An evaluation of lithium as an adjunct to carbimazole treatment in acute thyrotoxicosis. Acta Endocrinol 1976; 83: 86–97.PubMedGoogle Scholar
  104. 104.
    Ashkar F, Katims RB, Smoak WM, Gilson AJ. Thyroid storm treatment with blood exchange and plasmapheresis. JAMA 1970; 214: 1275–1279.Google Scholar
  105. 105.
    Papini P, Panunzi C, Pacella CM, et al. Percutaneous ultrasound-guided ethanol injection: a new treatment of toxic autonomously functioning thyroid nodules? J Clin Endocrinol Metab 1993; 76: 411–416.PubMedCrossRefGoogle Scholar
  106. 106.
    Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22: 263–277.Google Scholar
  107. 107.
    Das G, Kreiger M. Treatment of thyrotoxic storm with intravenous administration of propranolol. Ann Intern Med 1969; 70: 985–988.PubMedGoogle Scholar
  108. 108.
    Brunette DD, Rothong C. Emergency department management of thyrotoxic crisis with esmolol. Am J Emerg Med 1991; 9: 232–234.PubMedCrossRefGoogle Scholar
  109. 109.
    Benua RS, Becker DV, Hurley JR. Thyroid storm. In: Bardin CW, ed. Current Therapy in Endocrinology and Metabolism. 5th ed., Mosby, St Louis, 1994, pp. 75–77.Google Scholar
  110. 110.
    Mazzaferri EL, Skillman TG. Thyroid storm: A review of 22 episodes with special emphasis on the use of guanethidine. Arch Intern Med 1969; 124: 684–690.PubMedCrossRefGoogle Scholar
  111. 111.
    Davis LE, Lucas MJ, Hankins GDV, et al. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol 1988; 160: 63–70.Google Scholar
  112. 112.
    Seely BL, Burrow GN. Thyrotoxicosis in pregnancy. Endocrinologist 1991; 1: 409–417.CrossRefGoogle Scholar
  113. 113.
    Glinoer D, De Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71: 276–287.PubMedCrossRefGoogle Scholar
  114. 114.
    Goodwin TM, Montoro M, Mestman JH, et al. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab 1992; 75: 1333–1337.PubMedCrossRefGoogle Scholar
  115. 115.
    Norman RJ, Green-Thompsom RW, Jialal I, et al. Hyperthyroidism in gestational trophoblastic neoplasia. Clin Endocrinol 1981; 15: 395–401.CrossRefGoogle Scholar
  116. 116.
    Pekary AE, Jackson, IMD, Goodwin TM, Pang X-P, Hein MD, Hershman JM. Increased in vitro thyrotropic activity of partial sialated human chorionic gonadotropin extracted from hydatidiform moles of patients with hyperthyroidism. J Clin Endocrinol Metab 1993; 76: 70–74.PubMedCrossRefGoogle Scholar
  117. 117.
    Milham S. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology 1985; 32: 321.PubMedCrossRefGoogle Scholar
  118. 118.
    Momotani N, Noh J, Oyanagi H, et al. Antithyroid drug therapy for Graves’ disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med 1986; 315: 24–28.PubMedCrossRefGoogle Scholar
  119. 119.
    Hamburger JI. Diagnosis and management of Graves’ disease in pregnancy. Thyroid 1992; 2: 219–224.PubMedCrossRefGoogle Scholar
  120. 120.
    Amino N Tanizawa O, Mori H, et al. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves’ disease. J Clin Endocrinol Metab 1982; 55: 108–112.PubMedCrossRefGoogle Scholar
  121. 121.
    Burrow GN, Klatskin EH, Genel M. Intellectual development in children whose mothers received propylthiouracil during pregnancy. Yale J Med 1978; 51: 151–156.Google Scholar
  122. 122.
    Stoffer SS, Hamburger JI. Inadvertent 131I therapy for hyperthyroidism in the first trimester of pregnancy. J Nucl Med 1976; 17: 146–149.PubMedGoogle Scholar
  123. 123.
    Pruyn SC, Phelan JP, Buchanan GC. Long term propranolol therapy in pregnancy. Maternal and fetal outcome. Am J Obstet Gynecol 1979; 135: 485–489.PubMedGoogle Scholar
  124. 124.
    McKenzie JM, Zakarija M. Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992; 2: 155–159.PubMedCrossRefGoogle Scholar
  125. 125.
    McKenzie JM, Zakarija M. The clinical use of thyrotropin receptor antibody measurements. J Clin Endocrinol Metab 1989; 69: 1093–1096.PubMedCrossRefGoogle Scholar
  126. 126.
    Check JH, Rezvani I, Goodner D, Hooper B. Prenatal treatment of thyrotoxicosis to prevent intrauterine growth retardation. Obstet Gynecol 1982; 60: 122–124.PubMedGoogle Scholar
  127. 127.
    Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med 1995; 123: 572–583.PubMedGoogle Scholar
  128. 128.
    Rosier A, Litvin Y, Hage C, et al. Familial hyperthyroidism due to inappropriate thyrotropin secretion successfully treated with triiodothyronine. J Clin Endocrinol Metab 1982; 54: 76–82.CrossRefGoogle Scholar
  129. 129.
    Takeda T, Suzuki S, Liu R-T, DeGroot LJ. Triiodothyroacetic acid has a unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab 1995; 80: 2033–2040.PubMedCrossRefGoogle Scholar
  130. 130.
    Beck-Peccoz P, Piscitelli G, Cattaneo M, Faglia G. Successful treatment of hyperthyroidism due to nonneoplastic pituitary TSH hypersecretion with 3,5,3 ’-triiodothyroacetic acid (TRIAC). J Endocrinol Invest 1983; 6: 217–223.PubMedGoogle Scholar
  131. 131.
    Salmela P, Wide L, Juustila W, Ruokonen A. Effects of thyroid hormones (T4,T3), bromocryptine and TRIAC on inappropriate TSH hypersecretion. Clin Endocrinol 1988; 28: 497–507.CrossRefGoogle Scholar
  132. 132.
    Beck-Peccoz P, Mariotti S, Guillausseau P, et al. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201–995. J Clin Endocrinol Metab 1989; 68: 208–214.PubMedCrossRefGoogle Scholar
  133. 133.
    Weintraub G, Gershengorn M, Kourides I, Fein H. Inappropriate secretion of thyroid stimulating hormone. Ann Intern Med 1981; 95: 339–351.Google Scholar
  134. 134.
    Wynne AG, Gharib H, Schneithauer BW, Davis DH, Freeman SL. Hyperthyroidism due to inappropriate secretion of thyrotropin in 10 patients. Am J Med 1992; 92: 15–24.PubMedCrossRefGoogle Scholar
  135. 135.
    Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroidstimulating hormone-secreting pituitary adenomas: A follow-up of 52 patients. Ann Intern Med 1993; 119: 236–240.PubMedGoogle Scholar
  136. 136.
    Volpe R. Subacute (de Quervain’s) thyroiditis. Clin Endocrinol Metab 1979; 8: 81–95.PubMedCrossRefGoogle Scholar
  137. 137.
    Nikolai TF, Coombs GJ, McKenzie AK, et al. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med 1982; 142: 2281–2283.PubMedCrossRefGoogle Scholar
  138. 138.
    Roti E, Emerson CH. Postpartum thyroiditis. J Clin Endocrinol Metab 1992; 74: 3–5.PubMedCrossRefGoogle Scholar
  139. 139.
    Lambert M, Unger J, De Nayer P, et al. Amiodarone-induced thyrotoxicosis suggestive of thyroid damage. J Endocrinol Invest 1990; 13: 527–530.PubMedGoogle Scholar
  140. 140.
    Volpe R. The management of subacute (de Quervain’s) thyroiditis. Thyroid 1994; 3: 253–255.CrossRefGoogle Scholar
  141. 141.
    Shakir MKM, Michaels RD, Jays JH, Potter BB. The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. Ann Intern Med 1993; 118: 112–113.PubMedGoogle Scholar
  142. 142.
    Candrina R, DiStefano, O, Spandrio E, et al. Treatment of thyrotoxic storm by charcoal plasmaperfusion. J Endocrinol Invest 1989; 12: 133–134.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Douglas S. Ross

There are no affiliations available

Personalised recommendations